East-West Hepatocellular Carcinoma Study Group

This study has been completed.

Sponsor:

Information provided by:

University of Milan

ClinicalTrials.gov Identifier:

NCT01237132

First received: November 8, 2010

Last updated: NA

Last verified: December 2009

History: No changes posted

Tracking Information
First Received Date ^ICMJE	November 8, 2010
Last Updated Date	November 8, 2010
Start Date ^ICMJE	Not Provided
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE (submitted: November 8, 2010)	Overall survival of resected patients for HCC The primary endpoint of the study was the overall survival of patients resected for HCC in any stage of the BCLC classification.
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE (submitted: November 8, 2010)	Disease-free survival of resected patients for HCC The secondary endpoint was the disease-free survival of patients resected for HCC among the BCLC stages.
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	East-West Hepatocellular Carcinoma Study Group
Official Title ^ICMJE	EAST-WEST HEPATOCELLULAR CARCINOMA STUDY GROUP
Brief Summary	The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. The aim of this study was to investigate the role of hepatic resection in a large retrospective multicentric cohort of patients resected for HCC regardless of the BCLC indications.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Cohort Time Perspective: Retrospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	Patients affected by HCC
Condition ^ICMJE	Carcinoma, Hepatocellular
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	Not Provided
Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: clinical diagnosis of hepatocellular carcinoma candidate to liver resection as a curative treatment Exclusion Criteria: uncertain diagnosis of hepatocellular carcinoma uncertain follow-up data
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01237132
Other Study ID Numbers ^ICMJE	HCC EWE
Has Data Monitoring Committee	No
Responsible Party	GUIDO TORZILLI MD, PHD, UNIVERSITY OF MILAN
Study Sponsor ^ICMJE	University of Milan
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	University of Milan
Verification Date	December 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top